Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Abstract

The constitutive activation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has been demonstrated to be critical in clinical cancer patients as well as in laboratory cancer models including hematological malignancies. Great efforts have been made to develop inhibitors targeting this pathway in hematological malignancies but so far the efficacies of these inhibitors were not as good as expected. By analyzing existing literatures and datasets available, we found that mutations of genes in the pathway only constitute a very small subset of hematological malignancies. Deep understanding of the function of gene, the pathway and/or its regulators, and the cellular response to inhibitors, may help us design better drugs targeting the hematological malignancies.

• Authors: Yanan Gao, Chase Y Yuan, Weiping Yuan
• Journal: Stem cell investigation (Stem Cell Investig) Vol. 3 Pg. 31 ( 2016) ISSN: 2306-9759 [Print] China
• PMID: 27583254 (Publication Type: Journal Article, Review)